Multiple Sclerosis Drugs Market Research Report 2022-2028 | Share, Global Trends, Key Players, Growth Analysis

The Multiple Sclerosis Drugs Market size is expected to grow at an annual average of 6% during 2021-2027. Multiple sclerosis is a chronic inflammatory disease that causes demyelination, axonal amputation, and neurodegeneration of neurons in the brain and spinal cord. The body’s immune system targets neurons within the central nervous system and damages myelin. It is a potentially debilitating disease that disrupts the body’s communication and coordination functions. Symptoms of multiple sclerosis vary widely depending on the degree of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, convulsions, bladder dysfunction, cognitive changes, mood swings, and depression. Individuals suffering from severe MS experience language and motor problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS.

The following segmentation are covered in this report:

By Type 

• Immunosuppressants
• Immunomodulators

By Route Of Administration

• Oral
• Injectable
• Intravenous

Company Profile

• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sanofi
• F. Hoffmann-La Roche Ltd.
• Celgene Corporation
• Acorda Therapeutics, Inc.
• Biogen, Inc.
• Actelion Pharmaceuticals (Johnson & Johnson)
• EMD Serono (Merck KGaA)
• AbbVie, Inc.

Scope of the report

The research study analyses the Multiple Sclerosis Drugs Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Multiple Sclerosis Drugs Market Report

• What was the Multiple Sclerosis Drugs Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027)
• What will be the CAGR of Market during the forecast period (2021-2027)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
• Which manufacturer/vendor/players in the Multiple Sclerosis Drugs Market was the market leader in 2020?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.